Assessment of bone density and bone loss

Osteoporosis International

Volumn 6, Issue SUPPL. 2, 1996, Pages 3-5

  Eastell, R ^a,b  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER;

BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CONFERENCE PAPER; DRUG MONITORING; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FRACTURE; HEEL; HIGH RISK PATIENT; HUMAN; MEASUREMENT; OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0029740683     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf01625232     Document Type: Conference Paper

References (6)

1. A Consensus development conference: diagnosis, prophylaxis and treatmentof osteoporosis. Am J Med 1991;90:107-10.
2. Report of a WHO study group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series 843. WHO: Geneva 1994.
3. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-5.
4. Porter RW, Miller CG, Granger D, Palmer SB. Prediction of hip fracture in elderly women: a prospective study. BMJ 1990;301:638-41.
5. Liberman VA, Weiss SR, Brull J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in post-menopausal osteoporosis N Engl J Med 1995;333:1437-43.
6. Eastell R. Biochemical markers. Spine, State of the Art Review 1994;8:155-70.